Search clinical trials for: trastuzumab

Total 1298 results

AstraZeneca
Daiichi Sankyo

Not yet recruiting

HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada (HER-TEMPO)

Metastatic Breast Cancer | HER2-positive Breast Cancer | Unresectable Breast Cancer | HER2-low Expressing Breast Cancer

Canada
National Cancer Institute (NCI)

Not yet recruiting

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage... and other conditions
Huihua Xiong

Not yet recruiting

A Multicenter, Prospective Study of Diarrhea Tolerance of Pyrotinib Combined With Trastumab and Taxane in the First-line Treatment of HER2-positive Advanced Breast Cancer

Breast Cancer
University of Chicago

Not yet recruiting

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

Breast Cancer | HER2-positive Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

United States
Fondazione IRCCS Policlinico San Matteo di Pavia

Recruiting

Potential Protective Role of SGLT-2 Inhibitors for Chemotherapy-induced Cardiotoxicity (PROTECT)

Breast Cancer

Italy
Vastra Gotaland Region

Recruiting

NT-proBNP to Assess Trastuzumab-induced Cardiotoxicity

Breast Cancer | Treatment Side Effects | Cardiotoxicity

Sweden
Samsung Medical Center

Recruiting

The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.

HER2-positive Breast Cancer

Korea, Republic of
Fudan University

Not yet recruiting

Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer

Breast Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer

Advanced Breast Cancer | Metastatic Breast Cancer

China
Enliven Therapeutics

Recruiting

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

Colorectal Cancer | HER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2 Amplification | HER2 Positive Solid Tumors

United States
Boehringer Ingelheim

Not yet recruiting

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib in Combination With Trastuzumab Deruxtecan or With Trastuzumab Emtansine and to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Metastatic Breast Cancer | Esophageal Adenocarcinoma | Metastatic Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma
National Cancer Institute (NCI)

Not yet recruiting

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer

HER2-positive Breast Cancer
N.N. Petrov National Medical Research Center of...

Recruiting

Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast Cancer

Oligometastatic Disease | HER2-positive Metastatic Breast Cancer

Russian Federation
Henan Cancer Hospital

Not yet recruiting

Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer

Breast Cancer | HER2-positive Breast Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

First-line Treatment | HER2-positive Metastatic Breast Cancer

China
AstraZeneca
Daiichi Sankyo Co., Ltd.

Recruiting

A Study of T-DXd in Patients With Selected HER2-overexpressing Tumors

Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)

China
The First Affiliated Hospital with Nanjing Medical...
Anhui Provincial Cancer Hospital; Affiliated Hospital of Jiangnan University; The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School and other collaborators

Recruiting

The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study

Breast Cancer

China
Gruppo Oncologico del Nord-Ovest

Not yet recruiting

Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease (TRINITY)

Gastric Cancer | HER2-positive Gastric Cancer

Italy
Iambic Therapeutics, Inc

Recruiting

A Phase 1/1b Study of IAM1363 in HER2 Cancers

HER2 Mutation-Related Tumors

United States
Yonsei University

Not yet recruiting

Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases (ELPIS)

Non Small Cell Lung Cancer

Korea, Republic of
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial

Breast Cancer

China
UNICANCER
Servier

Not yet recruiting

Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer (TRIFLUOX-DP)

Metastatic Colorectal Cancer | Metastatic Gastroesophageal Adenocarcinoma | DPD Deficiency
Daiichi Sankyo

Recruiting

A Study of Valemetostat in Combination With DXd ADCs in Subjects With Solid Tumors

Advanced Solid Tumor

United States
Peking Union Medical College Hospital

Recruiting

PONV Prevention Via Percutaneous Nerve Electrical Stimulation on PC6

Postoperative Nausea and Vomiting

China
OnKure, Inc.

Recruiting

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer (PIKture-01)

Breast Cancer | Advanced Cancer

United States
Hospital Israelita Albert Einstein
AstraZeneca

Recruiting

Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil

Breast Cancer

Brazil
Rigshospitalet, Denmark

Not yet recruiting

The Effects of HER2 Receptor Signaling on Human Brown Fat Activity (HEAT)

Breast Cancer

Denmark
Hebei Medical University Fourth Hospital

Recruiting

The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).

Advanced Breast Cancer | HER2-positive Breast Cancer

China
Zhejiang Cancer Hospital

Recruiting

The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity (START)

Cardiotoxicity Induced by Drug Therapy for Breast Cancer

China
Daiichi Sankyo

Recruiting

A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)

Breast Cancer | Advanced Cancer | HER2-positive Breast Cancer | HER2-low Breast Cancer

China
Yizhuo Zhang

Recruiting

Ondansetron (ODF) Versus Ondansetron Intravenously for the Prevention of Chemotherapy-induced Nausea and Vomiting Compare in Children

Pediatric Solid Tumor, Unspecified, Protocol Specific

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer (RADIOCOM)

Chemotherapeutic Toxicity | Radiotherapy; Complications | PARP Inhibitor | Immune Checkpoint Inhibitor | Trastuzumab | Breast Cancer, Familial Male | CDK4/6 Inhibitor | Pertuzumab

China
Jamia Millia Islamia

Recruiting

Intraligamentary Injections and Post-endodontic Pain

Pulpitis

India
Institut für Klinische Krebsforschung IKF GmbH...
Medizinische Hochschule Hannover, Germany, Prof. Dr. Arndt Vogel; MSD Sharp...

Not yet recruiting

Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer (TRAP-BTC)

Biliary Tract Cancer | HER2 Gene Mutation
Daiichi Sankyo
AstraZeneca

Not yet recruiting

A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)

Metastatic Cancer | Advanced Cancer

Spain, Italy, Korea, Republic of, United States, United Kingdom, France, Taiwan, Japan, Belgium, China, Australia
MedSIR
Hoffmann-La Roche

Not yet recruiting

PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer (DEMETHER)

HER2-positive Breast Cancer
The Netherlands Cancer Institute
Seagen Inc.

Recruiting

Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study (TRAIN-4)

Breast Cancer

Netherlands
Nanfang Hospital, Southern Medical University

Recruiting

Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore

Gastric Cancer

China
Beijing 302 Hospital

Recruiting

Efficacy of T-Dxd in the Treatment of HER2-positive BCBM After Prior Pyrotinib

Breast Cancer

China
Xuekui Liu

Not yet recruiting

A Prospective, Single-arm Phase II Clinical Trial of Tislelizumab Combined With Platinum Doublet Neoadjuvant Therapy to Improve Mandibular Preservation in Resectable Locally Advanced Oral Squamous Cell Carcinoma. (B2023-153)

Oral Squamous Cell Carcinoma
Clinical Research Centre, Malaysia
University of Malaya; Ministry of Health, Malaysia

Recruiting

The Effect of SGLT-2 Inhibitors on Epicardial Adipose Tissue and Cardiac Function in T2DM Patients With CAD (EpiCAD) (EpiCAD)

Coronary Artery Disease

Malaysia
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy

Advanced Breast Cancer | Objective Response Rate | Trastuzumab Emtansine

China
Fudan University

Recruiting

Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer (Miracle-G)

Adenocarcinoma | Metastatic Cancer | Metastatic Gastric Cancer | Gastroesophageal Junction Adenocarcinoma | Oligometastatic Disease | Stomach Neoplasm | Adenocarcinoma of the Stomach | Gastroesophageal-junction Cancer | Metastatic Adenocarcinoma

China
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC; Genentech, Inc.

Recruiting

A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

Esophageal Cancer | Gastric Adenocarcinoma | HER2 Gene Mutation

United States
H. Lee Moffitt Cancer Center and Research Institute
National Comprehensive Cancer Network; Puma Biotechnology, Inc.

Recruiting

Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer

Gastric Cancer | GastroEsophageal Cancer

United States
Guangdong Provincial People's Hospital
Sun Yat-sen University; First Affiliated Hospital, Sun Yat-Sen University; Shantou...

Recruiting

Organoid-based Functional Precision Therapy for Advanced Breast Cancer (ORIENTA)

Advanced Breast Cancer | HER2-negative Breast Cancer

China
Adrienne G. Waks
Gilead Sciences

Recruiting

A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After progrEssion on ENhertu (SATEEN)

Breast Cancer Female | Breast Cancer Metastatic | Her 2 Positive Breast Cancer

United States
Jeeyun Lee

Not yet recruiting

Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer

Stomach Neoplasm
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer

HER2-PositiveRecurrent or Metastatic Breast Cancer

Search clinical trials for: trastuzumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cambodia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations